GlassScriptPhysician profile
Benjamin M Hayek
NPI 1932201498
$2,334.13
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $613.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $695.34 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.18 | 2019-2020 | |
| Amgen INC. | $225.44 | 2019 | |
| Avanir Pharmaceuticals, INC. | $117.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $97.27 | 2019 | |
| Novo Nordisk INC | $96.11 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $93.12 | 2019-2020 | |
| Lilly USA, LLC | $91.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $86.25 | 2019 | |
| Abbvie INC. | $86.04 | 2019-2020 | |
| Pfizer INC. | $62.16 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.19 | 2020 | |
| Amarin Pharma, INC. | $34.65 | 2019-2020 | |
| Vivus LLC | $34.08 | 2019 | |
| Astellas Pharma US INC | $20.94 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.76 | 2019 | |
| Merck Sharp & Dohme LLC | $14.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.32 | 2019 | |
| Allergan, INC. | $12.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hayek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.